StockData
CLDINYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CLDWW

Calidi Biotherapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.78−0.05 (-6.40%)

Close on Oct 19, 2026

Market cap
$1.11M
P/E (TTM)
–
Dividend yield
–

Calidi Biotherapeutics, Inc. revenue by segment

No segment breakdown reported

Calidi Biotherapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.